Archived explainer. For the current picture see today's BLTE page.
BELITE BIO INC ADR (BLTE) is up +13.16% in the latest session. Our newswire has captured 1 story on BLTE across 1 source in the last 36 hours, with AI sentiment reading bullish (avg 67/100).
BLTE stock rose 13.16% to $193.61 in the session, driven by the announcement that Belite Bio submitted a New Drug Application for Tinlarebant to treat Stargardt Disease Type 1 in Japan. The U.S. Food and Drug Administration has accepted the application with Priority Review and set a Prescription Drug User Fee Act target action date of February 12. This regulatory progress has generated investor optimism.
Belite Bio Inc announced the submission of its New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant. The FDA has accepted the New Drug Application with Priority Review for the same treatment. These developments mark a key regulatory milestone for the company's lead candidate. The news has been widely covered in the financial media, contributing to the sharp rise in the stock price.
The stock is currently trading within its 52-week range of $64.00 to $200.00. The company has a market capitalization of $7.8 billion but remains unprofitable, with an earnings per share of -2.74 for the trailing twelve months. Recent insider transactions include four sales totaling $3.0 million, with the most recent filing on August 14, 2026. These transactions include sales by the CFO, CEO, and Chief Medical Officer.
Investors should monitor the FDA's target action date of February 12 as well as the broader coverage landscape. Analysts have expressed varying levels of optimism, with price targets ranging from $206 to $303. The stock's performance will likely remain sensitive to regulatory developments and analyst sentiment in the coming weeks.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
U.S. Food and Drug Administration accepted the New Drug Application with Priority Review for tinlarebant for the treatment of Stargardt disease type 1; Prescription Drug User Fee Act target action date of February 12,...
More on BLTE: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier BLTE move explainers: 2026-09-08 · 2026-09-04